The device will be priced via a subscription model at $199 a month for five patients or $399 a month for unlimited use. A study found that the device had a sensitivity of 96% across all forms of skin cancer and different skin types. Another study showed that the device reduced the number of missed skin cancer diagnoses by half. The development of the DermaSensor device cost $25 million.
Key takeaways:
- The FDA has approved DermaSensor’s handheld device that uses artificial intelligence to non-invasively detect skin cancer.
- The device can detect all three common types of skin cancer and signals to physicians whether a suspicious lesion should be investigated further.
- The FDA authorized marketing for the device last week, but is also requiring that DermaSensor conduct additional post-market clinical validation performance testing.
- The device will be priced through a subscription model at $199 a month for five patients or $399 a month for unlimited use.